Combination therapy in light of emerging artemisinin resistance

Milestones in Drug Therapy

Volumn 41, Issue , 2012, Pages 213-225

  Noedl, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; HOST PATHOGEN INTERACTION; HUMAN; INFECTION PREVENTION; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL;

EID: 84866996818     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0480-2_11     Document Type: Article

References (48)

1. Ross R (1911) The prevention of malaria. John Murray, London
2. World Health Organization (2010) World Malaria Report 2009. WHO, Geneva
3. Bruce-Chwatt L (1988) History of malaria from prehistory to eradication. In: Wernsdorfer WH, McGregor IA (eds) Malaria. Principles and Practice of malariology. Churchill Livingstone, Edinburgh, pp 1-59
4. Nocht B, Werner H (1910) Beobachtungen ueber eine relative Chininresistenz bei Malaria aus Brasilien. Dtsch Med Wschr 36:1557-1560
5. Neiva A (1910) Ueber die Bildung einer chininresistenten Rasse des Malariaparasiten. Mem Inst Oswaldo Cruz 2:131-140
6. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song Y (1994) The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 107:709-711
7. Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O (2006) Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med 12:200-205
8. Olliaro P, Wells TN (2009) The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85(6):584-595
9. Peters W (1969) Drug resistance in malaria-a perspective. Trans R Soc Trop Med Hyg 63:25-45
10. Li GQ, Arnold K, Guo XB, Jian HX, Fu LC (1984) Randomised comparative study of mefloquine, qinghaosu and pyrimethamine-sulfadoxine in patients with falciparum malaria. Lancet 2:1360-1361
11. Peters W (1990) The prevention of antimalarial drug resistance. Pharmacol Ther 47:499-508
12. White NJ, Pongtavornpinyo W (2003) The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 270:545-554
13. Su X, Kirkman LA, Fujioka H, Wellems TE (1997) Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 91:593-603
14. Kremsner PG, Krishna S (2004) Antimalarial combinations. Lancet 364:285-294
15. Campbell CC (2009) Malaria control - addressing challenges to ambitious goals. N Engl J Med 361:522-523
16. Giao PT, de Vries PJ (2001) Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 40:343-373
17. Bloland PB, Ettling M, Meek S (2004) Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 78:1378-1388
18. Congpuong K, Bualombai P, Banmairuroi V, Na-Bangchang K (2010) Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria. Malar J 9:43
19. Bloland PB (2003) A contrarian view of malaria therapy policy in Africa. Am J Trop Med Hyg 68:125-126
20. Baird JK, Basri H, Purnomo BMJ, Subianto B, Patchen LC, Hoffman SL (1991) Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 44:547-552
21. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR (2002) Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209-218
22. Eastman RT, Fidock DA (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7:864-874
23. Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Viriyavejakul P, Kollaritsch H, Wiedermann G, Looareesuwan S (2001) In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance. Am J Trop Med Hyg 65:696-699
24. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA (2006) Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 194:528-535
25. Basco LK, Bickii J, Ringwald P (1998) In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother 42:2347-2351
26. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A (2006) Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76 T and pfmdr1 86Y. Infect Genet Evol 6(4):309-314
27. Olliaro P, Mussano P (2003) Amodiaquine for treating malaria. Cochrane Database Syst Rev CD000016
28. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, Farrar J (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363:18-22
29. Giao PT, de Vries PJ, le Hung Q, Binh TQ, Nam NV, Kager PA (2004) CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquoneproguanil against falciparum malaria in Vietnam. Trop Med Int Health 9:209-216
30. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620
31. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O (2006) Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960-1963
32. Krishna S, Pulcini S, Fatih F, Staines H (2010) Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends Parasitol 26(11):517-23
33. Noedl H, Socheat D, Satimai W (2009) Artemisinin-resistant malaria in Asia. N Engl J Med 361:540-541
34. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ et al (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467
35. Enserink M (2008) Signs of drug resistance rattle experts, Trigger Bold Plan. Science 322:1776
36. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C (2006) In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 11:211-219
37. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim P, Sem R, Socheat D et al (2006) Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 11:1360-1366
38. World Health Organization (1973) Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. WHO Technical Report Series, Geneva, 529
39. Noedl H (2005) Artemisinin resistance: how can we find it? Trends Parasitol 21:404-405
40. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NP, de Vries PJ, Dorsey G et al (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201:570-579
41. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME et al (1999) Averting a malaria disaster. Lancet 353:1965-1967
42. White NJ (1998) Preventing antimalarial drug resistance through combinations. Drug Resist Updat 1:3-9
43. Newton PN, Dondorp A, Green M, Mayxay M, White NJ (2003) Counterfeit artesunate antimalarials in southeast Asia. Lancet 362:169
44. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8:272-280
45. Thanh NV, Toan TQ, Cowman AF, Casey GJ, Phuc BQ, Tien NT, Hung NM, Biggs BA (2010) Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar J 9:181
46. Thang NDEA, le Hung X, le Thuan K, Xa NX, Thanh NN, Ky PV, Coosemans M, Speybroeck N, D'Alessandro U (2009) Rapid decrease of malaria morbidity following the introduction of community-based monitoring in a rural area of central Vietnam. Malar J 8:3
47. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ, White LJ (2009) The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 8:31
48. World Health Organization (2006) Guidelines for the treatment of malaria. WHO, Geneva